New hope for aggressive ovarian cancer: targeted drug combo enters trial
NCT ID NCT07311577
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests a new drug combination for people with a specific, high-risk type of ovarian cancer that has not yet been treated. The treatment includes a targeted drug (disitamab vedotin) plus standard chemotherapy and a blood-vessel blocker (bevacizumab). After initial treatment, some participants continue on maintenance therapy. The goal is to see if this approach helps keep the cancer from growing. About 43 adults with HER2-positive, HRD-negative advanced ovarian cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Cancer Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
-
Jiangsu Cancer Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.